Renal Osteodystrophy and New Approaches in Treatment

Yıl 2007, Cilt: 16 Sayı: 1, 35 - 49, 01.03.2007

Fadime Ersoy Dursun Ayhan Doğukan

Öz

Renal osteodystrophy is an important cause of morbidity and decreased quality of life in chronic renal failure. The pathogenesis is complex and includes alterations in the metabolism of calcium, phosphorus and vitamin D, disturbances in the secretion and regulation of parathyroid hormone. It is encompasses a spectrum of high-to low turnover skeletal lesions, and the impact of various therapies may change the histologic pattern.

Anahtar Kelimeler

Renal Osteodystrophy, Treatment

Renal Osteodistrofi ve Tedavide Yenilikler

Öz

Renal osteodistrofi, kronik böbrek yetmezliğinde morbidite ve hayat kalitesinin azalmasının önemli bir nedenidir. Patogenezi karmaşık olup kalsiyum, fosfor ve vitamin D metabolizmasında değişiklikler ve paratiroid hormon salgılanmasının düzenlenmesinde bozukluğu kapsar. Tedavi ile değişebilen yüksek ile düşük dönüşümlü kemik lezyonları ile karakterizedir.

Anahtar Kelimeler

Renal Osteodistrofi, Tedavi

Kaynakça

• Hruska K. Pathophysiology of renal osteodystrophy. Pediatr Neprol 2000; 14: 636-640.
• Hamdy NAT, Kanis JA, Beneton MNC. Effect of alfa-calcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-363.
• Goodman WG, Ramirez JA, Belin T. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160- 1166.
• Coen G. Adynamic bone disease: an update and overview. J Nephrol 2005; 18: 117-122.
• Sweeney WE, Jones WK, Harris HW, et al. Osteogenic protein-1 (OP-1) alters growth and differantiation in the developing metanephrops (abstract). Pediatr Res 1994; 35: A374.
• Rickard DJ, Hofbauer LC, Bonde SK, et al. Bone morphogenic protein-6 production in human osteoblastic cell lines. J Clin Invest 1998;101:413-422.
• Kurata S, Ishibashi M, Nishida H, et al. A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients. Ann Nucl Med 2004;18: 513-5188.
• Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use the biochemical markers and non-invasive methods;when bone biopsy is needed. Nephrol Dial Transplant 2000; 15 (Suppl 5): 8-14.
• Qi Q, Maunier-Faugere MC, Geng Z, et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631.
• Gerakis A, Hutchinson AJ, Apostolou T, et al. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996; 11: 2430-2438.
• Urena P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 1-7.
• Jrava C, Armas JR, Salgueira M, et al. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996;11(Suppl 3): 43-46.
• Couttenye MM, D’Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase
• of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1997; 12: 2144-2150.
• Ferreira A. Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy: what do we have, what do we need? Nephrol Dial Transplant 1998; 13 (Suppl 3): 29-32.
• Coen G, Ballant P, Bonucci E, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Mineral Res 1995; 10: 932-939.
• Mazzafero S, Pasquali M, Ballanti P, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995; 10: 52-58.
• Hamdy NAT, Risteli J, Beneton MNC, et al. Serum type I procollagen peptide : a non-invasive index of bone formation in patients on hemodialysis? Nephrol Dial Transplant 1994; 9: 511- 516.
• Urena P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Mineral Res 1995; 10: 52- 58.
• Ferreira A, Urena P, Ang KS, et al. Relationship between serum B2-mikroglobulin, bone histology and dialysis membranes in uraemic patients. Nephrol Dial Transplant 1995; 10: 1701-1707.
• Martin KJ, Gonzalez EA. Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001; 38: 1430-1436.
• Roussanne MC, Duchamblon P, Gogusev J, et al. Parathyroid hyperplasia in chronic renal failure: role of calcium, phosphate and calcitriol. Nephrol Dial Transplant 1999; 14 (Suppl 1): S68-S69.
• Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
• Chertow GM, Burke SK, Lazarus M, et al. Polyl (allylamine hydrochloride-RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
• Slatopolsky EA, Burke SK, Dillon MA and Rena Gel Study Group. RenaGel, a nonabsorbed calcium and alüminyum-free phophate binder, lowers serum phosphrus and parathyroid hormone. Kidney Int 1999; 33: 694-701.
• Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevalemer hydrochloride (RenaGel) with and without supplemental calcium. Clin Nephrol 1999; 51: 18-26. Locatelli F, D’Amico M. Pontoriero G. Lanthanum carbonate (Shire). Drugs 2003; 6: 688-695.
• Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyper-phosphataemia in renal failure and dialysis patients. Int J Clin Pract. 2005; 59:1091- 1096.
• Nolan CR, Qunibi WY. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl; 95: S13-S20.
• Hernandez JD, Wesseling K, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin dial 2005; 18: 290-295.
• Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266-275.
• Coen G, Mantella D, Manni M, et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68: 1840-1848.
• Greenbaum LA, Grenda R, Qiu P, et al. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 2005; 20: 622-630.
• Cannella G, Bonucci E, Rolla D, et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-1132.
• Bacchini G, Fabrizi F, Pontoriero G, et al. “Pulse oral” versus intravenous calcitriol therapy in
• chronic hemodialysis patients. A prospective and randomized study. Nephron 1997; 77: 267- 272.
• Ritz E, Schömig M, Bommer J. Osteodystrophy in the millennium. Kidney Int Suppl 1999; 73: S94-S98.
• Cheng S, Coyne D. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease. Expert Opin Pharmacother 2006; 7: 617-621.
• Zisman AL, Ghantous W, Schinleber P, et al. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005; 25: 591-595.
• Morii H. Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism. Clin Calcium. 2005; 15: 29-33.
• Hamada C, Hayashi K, Shou I, et al. Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. Perit Dial Int. 2005; 25: 570-575.
• Talalaj M, Kapitan-Malinowska B, Debski K, et al. Administration of 1 alpha-OH vitamin D3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade. Endokrynol Pol. 2005; 56: 225- 232.
• Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 supress parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via calcium receptor. J Clin Invest 1997; 100: 2977-2983.
• Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int Suppl 2005; 95: S33-S36.
• Schömig M, Ritz E. Management of disturbed calcium metabolism in uraemic patients:2.
• Indications for parathyroidectomy. Nephrol Dial Transplant 2000; 15(Suppl 5): 25-29.